Sei Investments Co. Purchases Shares of 38,152 Celldex Therapeutics, Inc. $CLDX

Sei Investments Co. acquired a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 38,152 shares of the biopharmaceutical company’s stock, valued at approximately $1,210,000.

Several other hedge funds also recently made changes to their positions in the business. Wilmington Savings Fund Society FSB acquired a new stake in Celldex Therapeutics during the third quarter valued at approximately $42,000. Russell Investments Group Ltd. grew its position in Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 501 shares during the last quarter. Quantbot Technologies LP acquired a new position in Celldex Therapeutics in the third quarter worth approximately $63,000. Kestra Advisory Services LLC bought a new position in shares of Celldex Therapeutics in the fourth quarter valued at $98,000. Finally, Headlands Technologies LLC bought a new position in shares of Celldex Therapeutics in the second quarter valued at $125,000.

Celldex Therapeutics Trading Up 3.2%

Shares of CLDX stock opened at $44.33 on Wednesday. The company has a market capitalization of $3.48 billion, a price-to-earnings ratio of -10.19 and a beta of 0.87. Celldex Therapeutics, Inc. has a 1-year low of $20.19 and a 1-year high of $44.60. The stock’s fifty day simple moving average is $35.76 and its 200-day simple moving average is $31.83.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.12. The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.73 million. On average, sell-side analysts predict that Celldex Therapeutics, Inc. will post -4.17 EPS for the current year.

Analysts Set New Price Targets

CLDX has been the subject of several research reports. Wells Fargo & Company raised their price objective on Celldex Therapeutics from $48.00 to $72.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Guggenheim boosted their target price on Celldex Therapeutics from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Monday, July 20th. Cantor Fitzgerald reduced their target price on Celldex Therapeutics from $67.00 to $61.00 and set an “overweight” rating for the company in a report on Wednesday, July 22nd. Canaccord Genuity Group decreased their price target on Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. Finally, Wall Street Zen upgraded Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, July 12th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $55.46.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.